SUMMARY
Defining the precise molecular strategies that coordinate patterns of transcriptional responses to specific signals is central for understanding normal development and homeostasis as well as the pathogenesis of hormone-dependent cancers. Here we report specific prostate cancer cell/macrophage interactions that mediate a switch in function of selective androgen receptor antagonists/modulators (SARMs) from repression to activation in vivo. This is based on an evolutionarily conserved receptor Nterminal L/HX 7 LL motif, selectively present in sex steroid receptors, that causes recruitment of TAB2 as a component of an N-CoR corepressor complex. TAB2 acts as a sensor for inflammatory signals by serving as a molecular beacon for recruitment of MEKK1, which in turn mediates dismissal of the N-CoR/HDAC complex and permits derepression of androgen and estrogen receptor target genes. Surprisingly, this conserved sensor strategy may have arisen to mediate reversal of sex steroid-dependent repression of a limited cohort of target genes in response to inflammatory signals, linking inflammatory and nuclear receptor ligand responses to essential reproductive functions.
INTRODUCTION
The pattern of transcriptional response to the multiple signaling factors impacting each cell reflects, in part, an ability to integrate these inputs into a coordinated program of gene activation and repression. The actions of nuclear receptors have provided an ideal model in which to investigate this question, as androgen and estrogen receptors can bind both to agonists, such as dihydrotestosterone (DHT) and 17-b-estradiol (E 2 ), or to selective androgen and estrogen receptor modulators (SARMs, SERMs), which act as antagonists or as weak agonists in a context-dependent fashion.
Androgens, acting via androgen receptor (AR), are essential for normal growth and function of the prostate gland and in all animal models of prostate carcinogenesis. While androgen ablation is a standard treatment for prostate cancer (Feldman and Feldman, 2001 ; reviewed in Debes and Tindall, 2004) , there is an invariant progression from androgendependent to androgen-independent growth, even though high levels of AR generally persist (Feldman and Feldman, 2001; Chen et al., 2004 ; reviewed in Debes and Tindall, 2004) . Resistance to antiandrogen treatment has been postulated to reflect diverse mechanisms such as changes of AR expression and functions (silencing of the AR gene, mutations in the AR sequence, and increased levels of AR), alterations of levels of nuclear receptor cofactors, activation of growth factor or kinase pathways, and decreased expression of tumor suppressors or increased expression of antiapoptotic genes (Feldman and Feldman, 2001; Chen et al., 2004 ; reviewed in Debes and Tindall, 2004) ; but each of these could only account for a subset of resistance events. Analogous to other members of the nuclear receptor superfamily, AR actions require AF-2 transcription-activation function and an extended N-terminal domain with a strong AF-1 function (Onate et al., 1998; Bevan et al., 1999) . Agonists and antagonists induce different conformations of helix 12, with antagonists blocking AF-2 function by preventing formation of an effective ''charge clamp'' for the LXXLL interaction motif (Darimont et al., 1998; Nolte et al., 1998; Shiau et al., 1998) .
Investigation of active repression of gene expression by unliganded nuclear receptors has led to the identification of the nuclear receptor corepressors, N-CoR (Hö rlein et al., 1995) and SMRT (Chen and Evans, 1995; Sande and Privalsky, 1996) , which contain multiple repressor domains that could transfer their active repression function, recruiting histone deacetylases (HDACs). Based on genetic analyses, N-CoR proves to be required for the inhibitory function of estrogen receptor (ER) antagonists (SERMs) (Jackson et al., 1997; Smith et al., 1997; Lavinsky et al., 1998 ; reviewed in Glass and Rosenfeld, 2000; McKenna and O'Malley, 2002) . N-CoR has been found as a component of many complexes, including TBL1/TBLR1/HDAC3/GPS2 (Guenther et al., 2000; Li et al., 2000; Wen et al., 2000; Zhang et al., 2002; Yoon et al., 2003) , TAB2/HDAC3 (Baek et al., 2002) , Sin3/HDAC1, 2 complexes (Alland et al., 1997; Heinzel et al., 1997; Nagy et al., 1997) , complexes containing SWI/SNF-related proteins (Underhill et al., 2000) , and multiple other complexes (reviewed in Jepsen and Rosenfeld, 2002) . Sequences referred to as the CoRNR box (Hu and Lazar, 1999) or alternatively as LXX I/H I XXX I/L motifs (Nagy et al., 1999; Perissi et al., 1999) , appear to bind in the hydrophobic pocket that is occupied by the coactivator LXXLL helical motifs upon binding of ligand.
Recently, it has been recognized that there is an increased monocyte/macrophage infiltration in the adipose tissue of obese individuals and that these macrophages may be a major localized source of the inflammatory cytokines that are linked to insulin resistance (Weisberg et al., 2003; Xu et al., 2003) . Among their phenotypic actions, proinflammatory signals can derepress genes regulated by the p50 homodimer of NF-kB DNA binding factors by dismissal of the N-CoR complex (Baek et al., 2002) , influencing the behavior of prostate cancer cells in vitro (Kim et al., 2005) . Based on analysis of IKKb gene-deleted mice, interruption of the IKK/ NF-kB pathway attenuates inflammation-associated tumors (Greten et al., 2004) . It is thus of particular interest to determine whether a macrophage/prostate cancer cell interaction occurs if it is a common event in prostate cancer and whether this serves to elicit inflammatory signals capable of impacting the therapeutic effectiveness of SARMs. These compounds typically function initially as antagonists in vivo but almost invariably become ineffective over a period of time (Feldman and Feldman, 2001; Chen et al., 2004; reviewed in Debes and Tindall, 2004) .
In this manuscript, we establish that specific interactions between prostate cancer cells and macrophages appear to occur in most prostate cancers examined and convert SARMs to function as agonists by activating a functional program of specific proinflammatory signals that cause dismissal of the N-CoR holocorepressor complex from AR. This derepression effect requires TAB2 (Takaesu et al., 2000) , recruited to steroid hormone receptors through a specific, evolutionarily conserved, N-terminal L/HX 7 LL motif found in sex steroid receptors but not in other nuclear receptors. This motif serves as a discriminatory molecular beacon for specific proinflammatory cytokine signals, modulating a coordinated program of gene derepression. One evolutionary basis for this signal processing module appears to be the importance of inflammatory signal-dependent derepression of a cohort of sex steroid-repressed genes in reproductive biology.
RESULTS

Macrophage/Prostate Cancer Cell Interaction Causes Resistance to SARMs
To examine potential direct interactions between macrophages and prostate cell lines, we initially used RWPE1-transformed prostate cells and fluorescein-labeled THP-1 monocytes/macrophages and found a specific RWPE1/ macrophage interaction ( Figure 1A ). Pretreatment of RWPE1 cells with TNFa, LPS, or IL-1 induced the expression of VCAM-1 (data not shown) and enhanced the engagement of macrophages ( Figures 1A and 1B) . We found that these interactions were blocked by addition of a specific VCAM-1 monoclonal IgG ( Figures 1A and 1B) . These data raised the possibility that such interactions might also operate in vivo in prostate cancer. We therefore examined tissue arrays containing patient-matched sections with both normal and cancer-containing regions of prostates, stained for CD68, a specific marker of macrophages. This revealed that virtually 100% of the tumor samples exhibited macrophage infiltration as well as stromal interactions with macrophages ( Figure 1C ). There was much less interaction between macrophages and histologically ''normal'' cellular areas in the resected tumors ( Figures 1C and 1D) .
Therefore, we considered that macrophage/prostate cancer cell interactions might represent a possible in vivo mechanism involved in SARM resistance in prostate cancer. We explored whether the direct cell-to-cell interactions that we observed between macrophages and prostate cancer cells might cause changes in the activity of SARMs based on macrophage activation and release of proinflammatory cytokines. Nuclear microinjection studies were performed in RWPE1 cells pretreated with TNFa, where indicated, using a prostate-specific antigen (PSA) promoter-controlled reporter. Following microinjection of the PSA reporter, THP-1 cells were added to the prostate cells for 6 hr and then either DHT or bicalutamide was added for 6 hr. We observed the expected activity of the PSA reporter whether or not the cells had been pretreated with TNFa ( Figure 1E) , with a robust increase in activity after DHT, but not bicalutamide (Figure 1E) . Addition of macrophages to untreated RWPE-1 cells clearly increased the basal activity, although less than TNFapretreated cells, due probably to lesser adhesion of macrophages to prostate cells ( Figure 1A) . In TNFa-pretreated RWPE1 cells cocultured with macrophages, there was an agonist-like induction of reporter activity in the presence of bicalutamide, which was reversed by the addition of VCAM-1 antibody prior to macrophage addition ( Figure 1E ). We observed similar effects using the promoter of another AR target gene, KLK2, in LNCaP cells ( Figure 1E ). To further test the role of IL-1b, one of the major cytokines secreted by macrophages that derepresses p50-dependent genes (e.g., KAI1), we blocked IL-1 signaling by adding IL-1 receptor antagonist (IL-1ra) or neutralizing antibodies to type I IL-1 (E) Effects of macrophage/prostate cell interaction on AR antagonist. RWPE1 and LNCaP cells were single-cell microinjected with lacZ reporters driven by the PSA and KLK2 promoters, respectively. After being incubated with THP-1 monocyte/macrophages and neutralizing antibodies against human VCAM-1 (aVCAM-1) where indicated, RWPE1 or LNCaP cells were treated with ligands and/or blocking reagents (IL-1ra: human IL-1 receptor antagonist; aIL-1RI: neutralizing antibodies against human IL-1 receptor type I). Data are represented as mean ± SEM.
receptor (a-IL-1RI) ( Figure S1 ) into the medium after microinjection of reporters. Under those conditions, the macrophage-induced agonistic activity of bicalutamide was efficiently abrogated ( Figure 1E ), suggesting an important role of IL-1 signaling in resistance to SARMs.
IL-1b Converts Androgen Antagonists to Function as Agonists
Because IL-1b blocks the activity of corepressors including N-CoR (Baek et al., 2002) , we then conducted mechanistic studies to investigate the role of N-CoR and other repressors in SARM-dependent transcriptional repression. Single-cell nuclear microinjection of specific a-N-CoR IgG abolished the repression of a reporter under control of an AR response element in the presence of bicalutamide (Figure 2A) . AR antagonists behaved as agonists in MEFs from N-CoR À/À mice, stimulating reporter gene expression (Figure 2B) . These results were validated using siRNAs against N-CoR (Perissi et al., 2004) , which reversed bicalutamidedependent repression function ( Figure 2C ), consistent with the finding that failure of N-CoR recruitment occurs in aggressive tumors with AR overexpression and antagonist resistance (Chen et al., 2004) . To a lesser extent, SMRT was also required for SARM-dependent repression (data not shown).
We observed the presence of individual components of many distinct N-CoR complexes on the PSA promoter (Cleutjens et al., 1996) in bicalutamide-treated cells using chromatin immunoprecipitation (ChIP) assay ( Figure 2D ), but it was unclear whether these complexes are independently recruited as distinct N-CoR complexes or combinatorially recruited as a holocomplex (Shang et al., 2002) . Sequential ChIP assay of the PSA promoter revealed that many components that mark the independently isolated N-CoR complex, including the TAB2/HDAC3-, the TBL1/TBLR1-, the Sin3-, and the Brg1-containing complexes, were apparently corecruited in bicalutamide-dependent repression ( Figure 2E ). In contrast, an MBD3-containing complex (Zhang et al., 1999) may not be simultaneously assembled with other components, such as the Sin3 complex, on the PSA promoter ( Figure 2E ). Injection of specific purified IgGs against HDAC1, 2, or 3 showed that blocking the actions of any of these HDACs relieved cyproterone (CPA)-dependent repression, while HDAC1 and 3, but not HDAC2, were required for bicalutamide-mediated repression (Figures 2F and 2G) . Because HDACs that lack functional HDAC activity failed to rescue the knockdown effects of each HDAC siRNA in the presence of bicalutamide or CPA (Figures S2A, S2B, and S2C) and functional HDAC2 and HDAC3 failed to compensate for the loss of HDAC1 activity ( Figure S2D ), distinct HDAC enzymatic activities are suggested to be combinatorially required for maintenance of the antagonistic effects of SARMs on AR.
Recombinant IL-1b ''switched'' bicalutamide or CPA to function as an agonist, and this switch could be overcome by overexpression of N-CoR ( Figure 3A ). Upon stimulation by IL-1b, there was a progressive and complete dismissal of all components of the N-CoR-containing complex recruited by SARM bound AR for the PSA promoter assessed using ChIP assay ( Figure 3B ). N-CoR was detected in both nuclear and cytoplasmic locations in either nontreated or SARM-treated LNCaP prostate cancer cells but became more preferentially localized to cytoplasm after IL-1b treatment ( Figure 3C ). Consistent with the observation that TAB2 is a substrate for MEKK1, potentially causing the exposure of a nuclear export signal (Baek et al., 2002) , IL-1b-dependent loss of the N-CoR complex from AR was accompanied by a transient recruitment of MEKK1 ( Figure 3B ). Intriguingly, MEKK1 remained transiently associated with the promoter after dismissal of TAB2, which may reflect subsequent MEKK1/coactivator interactions, as MEKK1/Tip60 interactions can be detected by coimmunoprecipitation analysis ( Figure S3A ). Injection of either aTAB2 or aMEKK1 IgG abolished the activation of an androgen-dependent reporter in the presence of IL-1b and SARM ( Figure 3D ). Similarly, IL-1b-dependent agonistic activity of SARMs was abolished using MEFs either from MEKK1 gene-deleted mice (Figure 3E) or from TAB2 gene-deleted mice ( Figure 3F ), supporting the model that MEKK1 recruitment to TAB2 is required for the removal of N-CoR complexes and derepression of AR target genes. In TAB2 À/À MEFs, the SARM bicalutamide acted as an antagonist even with IL-1b treatment unless TAB2 was reexpressed or N-CoR/SMRT expression was abrogated by microinjection of specific siRNAs (Figure 3G) . In MEKK1 À/À MEFs, we rescued SARM bound AR activation by IL-1b by expression of wild-type MEKK1 or a MEKK1 protein with a point mutation to block its internal ubiquitin ligase activity (C478A) (Lu et al., 2002) . MEKK1 harboring a mutation blocking its protein kinase activity (D1369A) failed to function in AR derepression ( Figure 3H ). An RNA-profiling experiment revealed that almost all DHTstimulated gene transcripts recorded were also induced by bicalutamide in the presence of IL-1b, suggesting that this strategy regulates most or all AR-dependent genes (Figure 4A , Table S1 ).
Molecular Mechanisms of Steroid Hormone Receptor-Specific Derepression by IL-1b
Analogous to events on SARM bound AR, IL-1b-dependent conversion of SERMs (4-hydroxytamoxifen, 4-OHT) to activators of estrogen receptor-a (ERa) also failed to occur in cells null for either MEKK1 or TAB2 ( Figures 4B and 4C ). Similarly, antagonists of progesterone receptor (PR) were also switched to agonists in response to IL-1b, and both MEKK1 and TAB2 were required for agonistic actions of PR antagonists ( Figure 4D ). In contrast, even in the same LNCaP cells, retinoic acid receptor-a (RARa)-dependent repression was not altered by IL-1b either in the absence of ligands or even with binding of the RARa antagonist LG815 ( Figure 4E ). Moreover, RARa-dependent activation or repression (mediated by N-CoR) was not altered by disrupting TAB2 or MEKK1 functions using IgGs or dominant negative mutant counterparts ( Figure 4F ). ChIP assays revealed that the N-CoR holocorepressor complex, including TBLR1, mSin3A/B-containing complexes, and HDAC3, was present on the RARb promoter ( Figure 4G ). On this RARa target, TAB2 recruitment could not be detected in either the presence or absence of antagonists. This is in contrast to the presence of TAB2 in the N-CoR holorepressor complex on the PSA promoter in response to SARMs ( Figure 4G and data not shown). The receptor specificity of the IL-1b response is consistent with the hypothesis that IL-1b-dependent dismissal of NCoR holocorepressor complexes on AR, ER, and PR requires the presence of a component of the N-CoR complex, TAB2, that is not successfully recruited to unliganded or to antagonist bound RXR/RAR complexes, raising the question of why TAB2 is recruited to some nuclear receptors but not to others. One striking difference between sex hormone receptors and retinoic acid and thyroid hormone receptors is the relative importance of the N terminus in gene activation events and the presence of distinct activation domains (AF1) in the N terminus of ER and AR (Alen et al., 1999; Bevan et al., 1999; Tremblay et al., 1999) . Indeed, the N-terminal domain of ERa is > 180 aa, and that of AR is > 530 aa, compared to a relatively short (<90 aa) RARa N terminus.
We therefore examined the possibility that the N termini of AR, ER, or PR harbored the key for inclusion of TAB2 into the N-CoR holocorepressor complex. Consistent with this model, we find that TAB2 can interact with the N terminus of either AR (aa 1-512) or ERa (aa 1-173) in coimmunoprecipitation assays ( Figure 5A ). Further, with removal of the AR N terminus (aa 2-500), in comparison to androgen holoreceptor, there was no change in the recruitment of receptors themselves and other components of the N-CoR holocomplex, including HDAC3, TBLR1, and mSin3A/B in response to SARMs, but there was a loss of ability to recruit TAB2 ( Figure 5B , and data not shown). A similar result was found with ERa, wherein the presence of the N terminus (aa 1-170) is required for recruitment of TAB2 but not for other components of the N-CoR holocomplex in response to SERMs (data not shown). Finally, with replacement of (or addition to) the RARa N terminus (aa 1-60) with that of either the AR (aa 1-512) or ERa (aa 1-173), the RARa fusion proteins (AR-N'/RAR, ER-N'/RAR) can now exhibit MEKK1-and TAB2-dependent activation with RARa antagonist or in the absence of ligands in response to IL-1b ( Figure 5C and data not shown). Further, a serial two-step ChIP assay confirmed that N-CoR and TBLR1 components were present on both RARa and the AR-N'/RARa fusion receptor and that TAB2 could be recruited only to the fusion receptor ( Figure 5C and data not shown), suggesting that the steroid hormone receptor N termini are required for TAB2 recruitment to the N-CoR complex during repression. Retinoic acid stimulated the chimeric RARa, but neither E 2 nor DHT exerted activation effects ( Figure 5C and data not shown).
To localize a potential interaction domain(s), HA-NLStagged fragments of ERa N terminus and endogenous TAB2 were tested by coimmunoprecipitation/Western blot analysis. These studies revealed that only aa 1-45 of the ERa N terminus permitted TAB2 binding ( Figure 5D ). Again, the initial 45 aa of ERa N terminus was sufficient to cause direct interactions with TAB2 using bacterially expressed ERa fragments. Further mapping revealed that this interaction was dependent upon the C terminus (aa 400-693) of TAB2, a region that also harbors the critical regulatory MEKK1 phosphorylation site (aa 419-423) and the NES site (aa 547-561) ( Figure 5E ). Finally, deletion of aa 1-45 of the ERa N-terminal sequence within the ERa-N'/RARa chimeric receptor caused loss of IL-1b response, while deletion of aa 46-90 or aa 91-135 failed to block IL-1b-induced activation ( Figure 5F ). Within the TAB2 regulatory N-terminal sequences of AR and of ERa, we identified a sequence, L/HXXAXXXXLL (referred to as L/HX 7 LL), conserved between species and between AR, ERa, and PR and also related to a sequence present in BCL3 ( Figure 5G ), which is recruited to the p50 site of KAI1, a site that also recruits TAB2 with the N-CoR holocomplex and that is derepressed in response to IL-1b (Baek et al., 2002) . These residues are predicted to form a specific putative helical structure (Reid et al., 2002) . To further test the hypothesis that this site is required or even sufficient to confer interactions with TAB2 and mediate IL-1b effects, we deleted the N-terminal 15 aa, including HX 7 LL sequence from the ERa-N'/RARa fusion protein (DHX 7 LL), finding that deletion of the sequence caused loss of its ability to transfer activation of RARa by IL-1b ( Figure 5H ). Replacement of the HX 7 LL sequence of ERa with the corresponding LX 7 LL sequence of AR, though not an AX 7 AA mutant AR sequence, was sufficient to restore IL-1b-mediated activation of ERa-N'/RARa on an RARE or on the RARb promoter ( Figure 5H and data not shown). A mutant (L14,15A) of ERa holoreceptor with disrupted HX 7 LL motif was found to lose response to IL-1b in the presence of antagonist, while the agonist-induced activation was fully intact ( Figure 5I ). As an independent confirmation, we transfected 293 cells with the tagged AR wild-type (LX 7 LL) or mutant (AX 7 AA) motif-containing RARa fusion receptors and tagged wild-type ERa or the ERa(L14,15A) mutant and performed a coimmunoprecipitation analysis, finding a decreased interaction of the mutant receptors with TAB2 ( Figures S3B and S3C) . Therefore, the ability to recruit TAB2 into the nuclear receptor-recruited N-CoR holocorepressor complex and to be derepressed by a proinflammatory cytokine are conferred by a specific, evolutionarily conserved sequence that is present in both AR and ERa.
To test whether competition for TAB2 binding to the L/ HX 7 LL motif might actually be sufficient to block IL-1b activation of androgen target genes by SARMs, we used the single-cell nuclear microinjection assay to introduce a 14mer synthetic peptide encompassing either the AR LX 7 LL motif or the same sequence with L/A substitutions (AX 7 AA) into cells expressing PSA promoter-dependent reporters. We found that the AR N-terminal LX 7 LL peptide specifically blocked IL-1b-mediated activation function of bicalutamide, while the mutated AX 7 AA sequence failed to inhibit induction ( Figure 5J) . Moreover, the antagonist/IL-1b-mediated induction of the endogenous AR gene target PSA was prevented by microinjection of LX 7 LL but not AX 7 AA peptide ( Figure 5K ). Therefore, this sequence is required and sufficient to mediate TAB2 recruitment and IL-1b-mediated derepression. To test whether the L/HX 7 LL motif is also crucial for macrophage-induced derepression in prostate cells, we performed nuclear microinjection of the AR-N' LX 7 LL 14mer peptide into RWPE1 cells pretreated with TNFa to induce VCAM-1 and interaction with THP-1 macrophages as described in Figure 1 . Intriguingly, the LX 7 LL-containing peptide, though not the AX 7 AA mutant, blocked the macrophage-induced agonistic ''switch'' of bicalutamide ( Figure 5L ), implying a potential therapeutic approach to treating hormone resistance induced by macrophage/cancer cell interaction in prostate cancer.
We finally explored the mechanisms by which MEKK1 induces TAB2/N-CoR dismissal from the target gene promoters in response to proinflammatory signals via the suggested MEKK1-dependent phosphorylation of TAB2 (Baek et al., 2002) . We performed coimmunoprecipitation of endogenous TAB2, N-CoR, and HA-tagged AR N terminus (1-512) after overexpression of MEKK1, observing that activation of MEKK1 kinase activity inhibited TAB2 interactions with the AR N terminus while enhancing its interactions with N-CoR, consistent with its function in removal of the N-CoR holocorepressor complex in derepression ( Figure S3D ).
Potential Physiological Roles of N-CoR/TAB2-Dependent Derepression
While these observations have produced initial evidence for an unexpected mechanism underlying some aspects of (E) GST pull-down assays using different fragments of ERa N terminus fused to GST and in vitro translated full-length, N-terminal (aa 1-399) or C-terminal (aa 400-693) TAB2. The Coomassie blue staining of the purified GST fusion proteins showed similar amounts used in the assays. (L) Macrophage/prostate cell interaction was set up as described in Figure 1 . By single-cell nuclear microinjection, the 14mer wt LX 7 LL and mutant AX 7 AA peptides were coinjected into RWPE1 prostate cells with a reporter driven by the PSA promoter, followed by the addition of ligands to the medium. Data are represented as mean ± SEM. SARM/SERM resistance in prostate and breast cancers, they simultaneously raise a perplexing issue. Given the evolutionary conservation of the L/HX 7 LL motif in specific nuclear receptors as well as the MEKK1/TAB2 effectors of the proinflammatory pathways, it is reasonable to conclude that there must be a physiologically important function that underlies this conserved response system. While many possible scenarios can be imagined, initial data led us to investigate the putative negative regulation of specific gene expression by E 2 . Indeed, a number of genes are reported, directly or indirectly, to be downregulated by estrogens (Frasor et al., 2003; Cicatiello et al., 2004 , Lin et al., 2004 . One such gene that is negatively regulated in response to E 2 is BMP7, and this would be predicted to exert key biological roles in several tissues. It has been suggested that E 2 bound ERa might be recruited to the BMP7 promoter and inhibit BMP7 expression by direct mechanisms (Kusumegi et al., 2004; Lin et al., 2004) . In fact, we found that the E 2 -dependent repression of BMP7 was relieved in response to IL-1b, following the same logic as the SARM/SERM derepression pathway ( Figure 6A ).
To better understand the extent to which the evolutionarily conserved mechanism that underlies resistance to SARM/ SERM regulates derepression of agonist bound sex steroid receptors, we compared a genome-wide analysis of promoter occupancy by ERa using a human 20 k array designed for a new assay of genome-wide location analysis, the ChIP-DSL-Chip method (I.G.-B., Y.-S. Kwon, M.G.R., X.-D. Fu, unpublished data), and previous analyses (Laganiere et al., 2005) to a list of genes reported to be downregulated in MCF7 cells in response to estrogen. Remarkably, only 17 of these downregulated genes actually exhibit promoter occupancy by ERa, suggesting that the direct negative regulation by E 2 may actually be limited to a rather discrete set of genes. We therefore tested these candidates and verified that the transcripts of eight genes, including ABCG2 and BCL3, were downregulated by E 2 , while the positive target pS2 was induced in MCF7 cells ( Figure 6A and data not shown). Importantly, addition of IL-1b reversed E 2 -dependent repression of these genes ( Figure 6A ), suggesting that the macrophage/IL-1b-mediated TAB2 derepression mechanism could underlie physiological events. To test the role of the N-CoR complex in E 2 -dependent repression, we evaluated the activity of the BMP7 or ABCG2 proximal promoter-controlled luciferase reporter in wt and N-CoR
MEFs. E 2 -induced repression of reporters was fully abolished in N-CoR knockout cells, revealing genetically the essential role of N-CoR in this event ( Figure 6B ). Using the BMP7-luciferase reporter in 293 cells, we confirmed that in the presence of ERa, E 2 decreased the reporter activity, whereas combination of E 2 and IL-1b restored the reporter activity to the baseline ( Figure 6C) . A dominant-negative mutant of TAB2, or TAB2 siRNA, abrogated derepression of the BMP7 promoter-dependent reporter, suggesting an essential role of TAB2 in this regulation. In contrast to wild-type ERa, an ERa construct harboring point mutations (E203A/ G204A) which prevent its DNA binding-dependent activities but not trans activities (Jakacka et al., 2001 ) fully abrogated the E 2 -mediated repression of the reporter, suggesting that the DNA binding ability of ERa is crucial for regulation of BMP7 expression ( Figure 6C ). We noted that the promoters of BMP7, ABCG2, and BCL3 each harbor putative half-ER binding sites. Consistent with these observations, ChIP analysis in MCF7 cells revealed that ERa, N-CoR, and TAB2 recruitment were enriched on the gene-regulatory regions of BMP7, ABCG2, and BCL3 upon E 2 treatment and that N-CoR/TAB2 were released in response to E 2 /IL-1b, although the relative amount of occupancy varied slightly on different promoters in response to E 2 and IL-1b ( Figure 6D ). Quantitative ChIP analysis of BMP7 promoter by real-time PCR confirmed a robust enrichment of ERa, N-CoR, and TAB2 triggered by E 2 and a complete dismissal of N-CoR and TAB2 by addition of IL-1b ( Figure 6E ). These data provide a physiological explanation for evolutionary conservation of the N-CoR/TAB2/L/HX 7 LL-dependent mechanism that underlies the ''switch'' of SARM function in response to IL-1b. This is particularly relevant in light of the fact that a key aspect of reproductive regulation, blastocyst implantation, involves a local induction of BMP7 in response to inflammatory signals (Monroe et al., 2000; Paria et al., 2001 ). The transporter ABCG2 plays a role in the placenta to protect the developing fetus from xenobiotic stimuli during gestation (Suzuki et al., 2003) , and BCL3 is linked to the regulation of the p50/52 homodimer-dependent subset of NF-kB targets. This pathway is, of course, likely to serve other biological functions, perhaps as a release of inhibition by unliganded receptor under specific protein kinase regulation, exerting roles in the immune and reproductive systems.
DISCUSSION
A Macrophage/Prostate Cancer Cell Signaling Pathway Causes Resistance to SARMs
The studies reported in this manuscript have provided initial evidence that interactions between macrophages and prostate cancer cells serve to mediate specific aspects of tumor behavior and responses to AR antagonists based on an evolutionarily conserved sensor system. Thus, in addition to clear roles of macrophages in atherosclerosis (reviewed in Li and Glass, 2002) , presumptive roles in diabetes mellitus, and correlation with vascularization of tumors (reviewed in Coussens and Werb, 2002) , macrophages appear capable of serving as an important aspect of SARM resistance in prostate cancer. Here we have found that macrophage/ prostate cancer interactions appear almost universal in clinical tumor samples, which could implicate macrophageproduced cytokines as a virtually ubiquitous signal in dictating prostate cancer cell responses. These observations are consistent with reports of monocytic/macrophage infiltration of prostate and breast cancers, particularly within surrounding stroma (Leek et al., 1996; Shimura et al., 2000) . Prostate cancer cells are reported to be capable of producing chemoattractants, e.g., GM-CSF, which might be the initial step for macrophage recruitment (Chung et al., 1999) . We have provided evidence that this macrophage/prostate cancer cell interaction, ultimately mediated via VCAM-1-dependent adhesion, causes macrophage activation and production of cytokines, including IL-1b, which are sufficient to cause resistance to antagonists (SARMs). These data suggest that the interaction between these two cell types serves, at least, as an important component of the ''resistance'' events in prostate cancer. This is consistent with the idea that, in addition to roles in infection and surveillance, the recruitment and activation of macrophages is probably a key aspect of many diseases. Because we have found that peptides corresponding to the L/HX 7 LL motif of AR or ERa can block macrophagedependent resistance, we suggest that this peptide inhibitor may serve as a prototype for identifying antiagonists that might act to prevent inflammatory cytokine-dependent switch in SARM or SERM function and hence ''block'' resistance. Our data would also suggest that IL-1b-mediated MEKK1 activation is likely to be the major macrophage-induced pathway for SARM resistance.
Molecular Mechanism of Proinflammatory SignalInduced Derepression of Specific Nuclear Receptors
The macrophage/prostate cancer cell interaction dictates a coordinated program of transcriptional response to an inflammatory cytokine resulting in derepression of a subset of N-CoR/SMRT-repressed genes based on the presence or absence of a specific molecular beacon, TAB2, which acts as a sensor of specific inflammatory signaling pathways. We find that recruitment of an N-CoR ''holocorepressor'' complex, including the TBL1/TBLR1-, mSin3-, and Brg1-containing components that are simultaneously recruited with N-CoR to AR, and multiple, required HDAC enzymatic activities serve to maintain repression on SARM bound AR. However, it is the inclusion of a specific component, TAB2, that underlies macrophage/prostate cancer cell derepression events. This complexity of the holocorepressor machinery may serve primarily to permit an ''integration'' of transcriptional responses to additional regulatory signals, exemplified by the selective derepression of specific cohorts of N-CoR-repressed genes in response to proinflammatory signaling events. Intriguingly, the molecular basis for recruitment of TAB2 to the N-CoR holocorepressor complex by AR, ER, and PR proves to lie in the specific interaction between TAB2 and an evolutionarily conserved N-terminal ''L/HX 7 LL'' sequence that permits recruitment of TAB2 to the N-CoR holocorepressor complex in a receptor/TAB2/N-CoR ternary complex ( Figure 5G ). This L/HX 7 LL TAB2 recognition motif can transfer recruitment of TAB2 and IL-1b-sensitive derepression to RARa that lacks the motif. In the case of p50 gene targets, a similar L/HX 7 LL sequence in BCL3 appears to mediate recruitment of TAB2 (our unpublished data). Therefore, the genomic response to IL-1b-dependent actions in derepression appears to be determined by a specific motif that serves to alter the composition of the N-CoR corepressor complex by recruiting the TAB2 component.
While the cytoplasmic function of TAB2 in IL-1b-induced activation of NF-kB p50/p65 heterodimers is unimpaired in TAB2-deficient embryonic fibroblasts, probably due to compensation by the related TAB3 (Sanjo et al., 2003) , the nuclear function of TAB2 in permitting IL-1b-dependent corepressor dissociation based on phosphorylation of TAB2 by MEKK1 (Baek et al., 2002 ) is lost in these cells. The potential conformational change in TAB2 upon phosphorylation simultaneously weakens its association with the AR/ER N terminus while enhancing its association with the N-CoR complex, which probably enables it to mediate dismissal of the entire N-CoR ''holocorepressor'' complex. Thus, DNA binding factor-specific recruitment of certain components of the corepressor holocomplex can serve as the ''molecular beacon'' for integrating nuclear transcriptional responses of different signaling pathways ( Figure 6F) , accounting for the resistance of other nuclear receptors like RARa to IL-1b signals.
Negative Gene Regulation As the Evolutionary Basis of the L/HX 7 LL/TAB2 Mechanism Based on the data presented here, we are tempted to suggest that this regulatory mechanism selective for sex steroid receptors arose in the context of gene inhibition by estrogen, androgen, and/or progesterone agonists. Here, on the promoters of BMP7, ABCG2, and BCL3, E 2 causes recruitment of the ERa/N-CoR/TAB2 complex, and IL-1b reverses this E 2 -dependent repression along the N-CoR/TAB2-dependent pathway. In the absence of N-CoR, E 2 -dependent repression is abolished, and macrophage/IL-1b-induced derepression is reversed by inhibition of TAB2. This provides at least one physiological explanation for this evolutionarily conserved L/HX 7 LL-dependent TAB2 recruitment and suggests that this mechanism, which derepresses a subset of E 2 -repressed genes in response to inflammatory signals, may play critical roles in several biological processes, particularly in reproductive biology. Indeed, macrophages are intimately connected with the development of hormone responsive tissues and reproductive organs (Cohen et al., 1999; Gouon-Evans et al., 2000) . It is intriguing to note that blastocyst implantation into the uterus constitutes an ''inflammatory event'' with regulated production of cytokines such as IL-1b and the closely related IL-18 (de los Santos et al., 1996) by both maternal cells and the blastocyst itself, which in turn direct remodeling of endometrium at the site of implantation. Strikingly, BMP7 expression is locally induced in the tissue immediately adjacent to the implanting blastocyst, exactly at the putative site of IL-1 action in the implantation process (Paria et al., 2001) . Therefore local induction of estrogen-inhibited BMP7 levels by inflammatory signals may facilitate the changes in uterine tissue organization necessary for blastocyst invasion and implantation. The induction of parturition has recently been proposed to involve activated, IL-1b-producing macrophages recruited into the uterine wall in response to signals from the maturing fetus (Condon et al., 2004) , an event which may also underlie preterm labor invoked by uterine infection; it is tempting to speculate similar TAB2/PR-mediated events. The ABCG2 gene encodes an ATP binding cassette (ABC) family half-transporter protein that is highly expressed in the placenta, where it has been implicated in protecting the developing fetus from xenobiotics during gestation (Suzuki et al., 2003) , consistent with a role in protecting sensitive tissues from cytotoxic, mutagenic, or hormonal stimuli. BCL3 serves as the transactivating component of transcription factor complexes containing NFkB1/p50 or NFkB2/p52 homodimers, which have been implicated in the pathogenesis of multiple hormonedependent cancers. Thus, it appears reasonable to suggest that the ability of inflammatory signals to reverse sex hormone-dependent gene repression is an important biological strategy, related to reproduction and probably other critical aspects of mammalian homeostasis.
In conclusion, our findings have provided evidence for a macrophage/prostate cancer regulatory axis that causes derepression of SARM actions by selective inclusion of TAB2 in the recruited N-CoR holocorepressor complex, and they exemplify a powerful sensor-based strategy of integrating genome-wide responses to specific signaling pathways, apparently of particular physiological relevance in reversing negative gene regulation events by the sex steroids. Defining this macrophage/cancer cell functional interaction as a component in resistance may provide additional strategies to modify therapeutic approaches to specific cancers.
EXPERIMENTAL PROCEDURES
Materials and Reagents
The following antibodies were obtained from Santa Cruz Biotechnology: a-AR, ERa, HDAC1, HDAC2, HDAC3, MBD3, MEKK1, MEK1, BRG1, and mSin3A/B. See Supplemental Data for all other antibodies and reagents.
Macrophage Binding Assay RWPE-1 cells were seeded on glass coverslips at subconfluent density and subsequently treated with cytokines for 6 hr. THP-1 cells were labeled with 3 0 -O-Acetyl-2 0 ,7 0 -bis(carboxyethyl)-4 or 5-carboxyfluorescein diacetoxymethyl ester (BCECF-AM) (Molecular Probes, Inc) following manufacturer's instructions. The labeled macrophages were resuspended in DMEM and added in a small volume to the RWPE-1 cells and incubated with gentle agitation for 30 min. Coverslips were washed with PBS and either mounted for microscopy or quantitatively analyzed by flourimetry.
Small Interfering RNA The small interfering RNA (siRNAs) were delivered into cells by single-cell microinjection or transfection using Lipofectamine 2000 (Invitrogen). Information of siRNAs is available in Supplemental Data.
Single-Cell Nuclear Microinjection Assays and Luciferase Reporter Assays
Microinjection assays and Luciferase reporter assays were carried out as previously described (Kamei et al., 1996; Heinzel et al., 1997) . Details are available in Supplemental Data.
Chromatin Immunoprecipitation Assays
The ChIP assay was conducted as previously described (Shang et al., 2000; Zhu et al., 2004) . Details are described in Supplemental Data.
RNA Profiling
GEArray Q Series Human Androgen Signaling and Prostate Cancer Gene Array (HS-031, Superarray Bioscience, Frederick, MD) was used to perform RNA expression profiling experiments of AR target genes. See Supplemental Data for details.
RT-PCR and Real-time Q-PCR
Semi-quantitative RT-PCR was carried out as described (Zhu et al., 2004) . For real-time Q-PCR, standard procedure was followed according to the Mx3000P Real-Time PCR Systems and the Brilliant QPCR reagent kits (Stratagene). Details are available in Supplemental Data.
Tissue Microarray and Immunohistochemistry
Prostate tissue microarrays (Cat# A302) were purchased from ISU Abxis (Seoul, South Korea) and stained as previously described (Zhu et al., 2004) . All other experimental procedures are available in Supplemental Data.
Supplemental Data
Supplemental Data include three figures, one table, Experimental Procedures, and References and can be found with this article online at http:// www.cell.com/cgi/content/full/124/3/615/DC1/.
